Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, Extranodal NK-T-Cell 2Recurrence 1Pleural Effusion, Malignant 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 4Carboplatin 2viscum album peptide 1sugemalimab 1rilotumumab 1ganitumab 1endostar protein 1Zoledronic Acid 1Valacyclovir 1Thiostrepton 1Surgical Procedures, Operative 1Paclitaxel 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Etoposide 1Darbepoetin alfa 1Cetuximab 1Catheters, Indwelling 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pleural Effusion, Malignant × sugemalimab × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡